论文部分内容阅读
目的探讨TGF-β1和CD105在胰腺癌生长、浸润、转移过程中的作用,为对患者进行预后判断及生物治疗提供理论依据。方法应用免疫组织化学S-P法检测TGF-β1、CD105在52例胰腺癌和10例非肿瘤性胰腺组织中的表达,分析它们与胰腺癌临床病理参数及患者生存率的关系。结果TGF-β1在非肿瘤性胰腺组织、胰腺癌中的阳性表达率分别为30%和80.77%,两者间的差异具有统计学意义(P<0.01)。TGF-β1的表达强度与胰腺癌临床分期及淋巴结有无转移呈正相关(P<0.01)。在52例胰腺癌中,CD105标记的微血管密度(Micro Vessel Den-sity,MVD)明显高于非肿瘤性胰腺组织(P<0.01)。胰腺癌分化程度越低,CD105标记的MVD值越高,并且TNM分期Ⅲ、Ⅳ期MVD值显著高于Ⅰ、Ⅱ期(P<0.01),淋巴结转移组的MVD值显著高于无淋巴结转移组(P<0.01)。此外,生存单因素分析TGF-β1、CD105与胰腺癌的预后有关(P<0.01)。结论TGF-β1和CD105在胰腺癌生长、浸润和转移过程中发挥了一定的作用。
Objective To investigate the role of TGF-β1 and CD105 in the growth, invasion and metastasis of pancreatic cancer and to provide a theoretical basis for the prognosis and biological treatment of patients. Methods The expressions of TGF-β1 and CD105 in 52 cases of pancreatic cancer and 10 cases of non-tumorous pancreatic tissue were detected by immunohistochemical S-P method. The relationship between TGF-β1 and clinicopathological parameters and the survival rate of pancreatic cancer were analyzed. Results The positive rates of TGF-β1 in non-neoplastic pancreatic cancer and pancreatic cancer were 30% and 80.77%, respectively, with statistical significance (P <0.01). The expression of TGF-β1 was positively correlated with clinical stage and lymph node metastasis (P <0.01). In 52 cases of pancreatic cancer, the microvessel density (MVD) of CD105 was significantly higher than that of non-neoplastic pancreatic tissue (P <0.01). The lower the degree of differentiation of pancreatic cancer, the higher the MVD value of CD105 labeling, and the MVD in stages Ⅲ and Ⅳ of TNM stage were significantly higher than those in stage Ⅰ and Ⅱ (P <0.01). The MVD in lymph node metastasis group was significantly higher than that in non-lymph node metastasis group (P <0.01). In addition, survival univariate analysis of TGF-β1, CD105 and prognosis of pancreatic cancer (P <0.01). Conclusion TGF-β1 and CD105 play a role in the growth, invasion and metastasis of pancreatic cancer.